Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.58 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.55 |
| ▸ | HINT1 | P49773 | 3/20 | 0.55 |
| ▸ | KRAS | P01116 | 9/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.54 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18271828 | 0.93 | TGM2 (0.61) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL21184238 | 0.93 | NT5E (0.71) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL25391360 | 0.89 | TAS1R3 (0.70) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL720437 | 0.89 | TAS1R3 (0.70) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL14576179 | 0.89 | TAS1R3 (0.70) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL600378 | 0.89 | TAS1R3 (0.70) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL26067681 | 0.89 | TAS1R3 (0.70) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL21184323 | 0.89 | TGM2 (0.68) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL19325472 | 0.89 | TGM2 (0.68) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL18763616 | 0.89 | TGM2 (0.68) | NT5ETGM2TAS1R3TAS1R1FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | RNGTT, RNMT, NSUN2 | NT5E 572/4885TGM2 3563/4885TAS1R3 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.